X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Thumbnail
Here's why investors are hesitant about the latest high-profle healthcare company to go public. [Read More]
Thumbnail
Results from a study of Trodelvy presented over the weekend suggest Gilead Sciences' $21 billion buyout offer was a smart move. [Read More]
Thumbnail
Here's what you should know about the experimental treatment that sent this biotech stock rocketing higher. [Read More]
Thumbnail
Find out what's behind their big run-ups to see if they can make it happen again. [Read More]
Save As
Preview
Preview